Priyesh A Patel1, Xin Zhao2, Gregg C Fonarow2, Barbara L Lytle2, Eric E Smith2, Ying Xian2, Deepak L Bhatt2, Eric D Peterson2, Lee H Schwamm2, Adrian F Hernandez2. 1. From the Duke Clinical Research Institute, Durham, NC (P.A.P., X.Z., B.L.L., Y.X., E.D.P., A.F.H.); Ronald-Reagan University of California, Los Angeles Medical Center, UCLA Department of Medicine, Los Angeles, CA (G.C.F.); Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada (E.E.S.); Brigham and Women's Hospital (D.L.B.) and Massachusetts General Hospital (L.H.S.), Harvard Medical School, Boston, MA; and Duke University Medical Center, Durham, NC (E.D.P., A.F.H.). priyesh.patel@dm.duke.edu. 2. From the Duke Clinical Research Institute, Durham, NC (P.A.P., X.Z., B.L.L., Y.X., E.D.P., A.F.H.); Ronald-Reagan University of California, Los Angeles Medical Center, UCLA Department of Medicine, Los Angeles, CA (G.C.F.); Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada (E.E.S.); Brigham and Women's Hospital (D.L.B.) and Massachusetts General Hospital (L.H.S.), Harvard Medical School, Boston, MA; and Duke University Medical Center, Durham, NC (E.D.P., A.F.H.).
Abstract
BACKGROUND: Novel oral anticoagulants (NOACs) have been shown to be at least as good as warfarin for preventing stroke or transient ischemic attack in patients with atrial fibrillation, yet diffusion of these therapies and patterns of use among atrial fibrillation patients with ischemic stroke and transient ischemic attack have not been well characterized. METHODS AND RESULTS: Using data from Get With The Guidelines-Stroke, we identified a cohort of 61 655 atrial fibrillation patients with ischemic stroke or transient ischemic attack hospitalized between October 2010 and September 2012 and discharged on warfarin or NOAC (either dabigatran or rivaroxaban). Multivariable logistic regression was used to identify factors associated with NOAC versus warfarin therapy. In our study population, warfarin was prescribed to 88.9%, dabigatran to 9.6%, and rivaroxaban to 1.5%. NOAC use increased from 0.04% to a 16% to 17% plateau during the study period, although anticoagulation rates among eligible patients did not change appreciably (93.7% versus 94.1% from first quarter 2011 to second quarter 2012), suggesting a trend of switching from warfarin to NOACs rather than increased rates of anticoagulation among eligible patients. Several bleeding risk factors and CHA2DS2-VASc scores were lower among those discharged on NOAC versus warfarin therapy (47.9% versus 40.9% with CHA2DS2-VASc ≤5, P<0.001 for difference in CHA2DS2-VASc). CONCLUSIONS: NOACs have had modest but growing uptake over time among atrial fibrillation patients hospitalized with stroke or transient ischemic attack and are prescribed to patients with lower stroke risk compared with warfarin.
BACKGROUND: Novel oral anticoagulants (NOACs) have been shown to be at least as good as warfarin for preventing stroke or transient ischemic attack in patients with atrial fibrillation, yet diffusion of these therapies and patterns of use among atrial fibrillationpatients with ischemic stroke and transient ischemic attack have not been well characterized. METHODS AND RESULTS: Using data from Get With The Guidelines-Stroke, we identified a cohort of 61 655 atrial fibrillationpatients with ischemic stroke or transient ischemic attack hospitalized between October 2010 and September 2012 and discharged on warfarin or NOAC (either dabigatran or rivaroxaban). Multivariable logistic regression was used to identify factors associated with NOAC versus warfarin therapy. In our study population, warfarin was prescribed to 88.9%, dabigatranto 9.6%, and rivaroxaban to 1.5%. NOAC use increased from 0.04% to a 16% to 17% plateau during the study period, although anticoagulation rates among eligible patients did not change appreciably (93.7% versus 94.1% from first quarter 2011 to second quarter 2012), suggesting a trend of switching from warfarin to NOACs rather than increased rates of anticoagulation among eligible patients. Several bleeding risk factors and CHA2DS2-VASc scores were lower among those discharged on NOAC versus warfarin therapy (47.9% versus 40.9% with CHA2DS2-VASc ≤5, P<0.001 for difference in CHA2DS2-VASc). CONCLUSIONS:NOACs have had modest but growing uptake over time among atrial fibrillationpatients hospitalized with stroke or transient ischemic attack and are prescribed to patients with lower stroke risk compared with warfarin.
Authors: Andrew J Karter; Melissa M Parker; Howard H Moffet; Ameena T Ahmed; Julie A Schmittdiel; Joe V Selby Journal: Health Serv Res Date: 2009-06-03 Impact factor: 3.402
Authors: James V Freeman; Ruo P Zhu; Douglas K Owens; Alan M Garber; David W Hutton; Alan S Go; Paul J Wang; Mintu P Turakhia Journal: Ann Intern Med Date: 2010-11-01 Impact factor: 25.391
Authors: L Samuel Wann; Anne B Curtis; Kenneth A Ellenbogen; N A Mark Estes; Michael D Ezekowitz; Warren M Jackman; Craig T January; James E Lowe; Richard L Page; David J Slotwiner; William G Stevenson; Cynthia M Tracy; Valentin Fuster; Lars E Rydén; David S Cannom; Harry J Crijns; Anne B Curtis; Kenneth A Ellenbogen; Jonathan L Halperin; G Neal Kay; Jean-Yves Le Heuzey; James E Lowe; S Bertil Olsson; Eric N Prystowsky; Juan Luis Tamargo; L Samuel Wann; Alice K Jacobs; Jeffrey L Anderson; Nancy Albert; Mark A Creager; Steven M Ettinger; Robert A Guyton; Jonathan L Halperin; Judith S Hochman; Frederick G Kushner; Erik Magnus Ohman; William G Stevenson; Clyde W Yancy Journal: Circulation Date: 2011-02-14 Impact factor: 29.690
Authors: Brian F Gage; Yan Yan; Paul E Milligan; Amy D Waterman; Robert Culverhouse; Michael W Rich; Martha J Radford Journal: Am Heart J Date: 2006-03 Impact factor: 4.749
Authors: Benjamin A Steinberg; Dajuanicia N Holmes; Jonathan P Piccini; Jack Ansell; Paul Chang; Gregg C Fonarow; Bernard Gersh; Kenneth W Mahaffey; Peter R Kowey; Michael D Ezekowitz; Daniel E Singer; Laine Thomas; Eric D Peterson; Elaine M Hylek Journal: J Am Heart Assoc Date: 2013-11-25 Impact factor: 5.501
Authors: Daniel K Nishijima; Samuel Gaona; Trent Waechter; Ric Maloney; Troy Bair; Adam Blitz; Andrew R Elms; Roel D Farrales; Calvin Howard; James Montoya; Jeneita M Bell; Victor C Coronado; David E Sugerman; Dustin W Ballard; Kevin E Mackey; David R Vinson; James F Holmes Journal: Prehosp Emerg Care Date: 2016-09-16 Impact factor: 3.077
Authors: Matthew Alcusky; Anne L Hume; Marc Fisher; Jennifer Tjia; Robert J Goldberg; David D McManus; Kate L Lapane Journal: Drugs Aging Date: 2018-12 Impact factor: 3.923
Authors: Javier A Valle; Susan Shetterly; Thomas M Maddox; P Michael Ho; Steven M Bradley; Amneet Sandhu; David Magid; Thomas T Tsai Journal: Circ Cardiovasc Interv Date: 2016-06 Impact factor: 6.546
Authors: Nicole B Sur; Kefeng Wang; Marco R Di Tullio; Carolina M Gutierrez; Chuanhui Dong; Sebastian Koch; Hannah Gardener; Enid J García-Rivera; Juan Carlos Zevallos; W Scott Burgin; David Z Rose; Jeffrey J Goldberger; Jose G Romano; Ralph L Sacco; Tatjana Rundek Journal: Stroke Date: 2019-05-14 Impact factor: 7.914
Authors: Darae Ko; Faisal Rahman; Maria A P Martins; Elaine M Hylek; Patrick T Ellinor; Renate B Schnabel; Emelia J Benjamin; Ingrid E Christophersen Journal: Nat Rev Cardiol Date: 2016-10-27 Impact factor: 32.419
Authors: Daniel K Nishijima; Samuel D Gaona; Trent Waechter; Ric Maloney; Troy Bair; Adam Blitz; Andrew R Elms; Roel D Farrales; Calvin Howard; James Montoya; Jeneita M Bell; Mark Faul; David R Vinson; Hernando Garzon; James F Holmes; Dustin W Ballard Journal: Ann Emerg Med Date: 2017-02-24 Impact factor: 5.721
Authors: Utibe R Essien; DaJuanicia N Holmes; Larry R Jackson; Gregg C Fonarow; Kenneth W Mahaffey; James A Reiffel; Benjamin A Steinberg; Larry A Allen; Paul S Chan; James V Freeman; Rosalia G Blanco; Karen S Pieper; Jonathan P Piccini; Eric D Peterson; Daniel E Singer Journal: JAMA Cardiol Date: 2018-12-01 Impact factor: 14.676